Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway

Table 3 Univariate and multivariate Cox proportional hazards models for overall survival of stage IV colorectal cancers

	Univariate analysis		Multivariate analysis
Variable	HR (95%CI)	P value	HR (95%CI)	P value
Differentiation (undifferentiated/differentiated)	2.20 (1.31-3.72)	0.003	1.95 (1.07-3.56)	0.030
Tumor location (proximal colon/distal colon, rectum)	1.66 (1.16-2.38)	0.005	1.60 (1.06-2.42)	0.025
Adjuvant chemotherapy (treatment/no-treatment)	0.42 (0.27-0.66)	< 0.001	0.47 (0.27-0.81)	0.006
Annexin A10 (expression/no-expression)	3.13 (1.83-5.38)	< 0.001	2.38 (1.18-4.83)	0.016
Age (yr) (≥ 65/< 65)	1.54 (1.10-2.15)	0.012	1.37 (0.92-2.03)	0.123
Gross pattern (ulcerative/fungating)	1.41 (1.01-1.96)	0.042	1.18 (0.81-1.71)	0.387
CIMP (CIMP-P/CIMP-N)	2.24 (1.24-4.06)	0.008	1.13 (0.44-2.89)	0.801
MSI (MSI/MSS)	2.46 (1.08-5.63)	0.033	1.46 (0.44-4.86)	0.540
BRAF mutation (Mt/Wt)	2.42 (1.12-5.19)	0.024	1.67 (0.71-3.91)	0.239
Sex (male/female)	1.03 (0.74-1.45)	0.858	-	-
KRAS mutation (Mt/Wt)	1.09 (0.75-1.58)	0.653	-	-

HR: Hazard ratio; CI: Confidence interval; CIMP-P: CpG island methylator phenotype-positive; CIMP-N: CpG island methylator phenotype-negative; MSI: Microsatellite instability; MSS: Microsatellite stable; Mt: Mutant type; Wt: Wild type.